Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 55287L101 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Deep Track Capital, LP
13G/A
Amendment 2
|
3.6% |
8/14/2026
Event 6/30/2026
|
|
| Deep Track Capital, LP | 3.6% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 3.6% | ||
| David Kroin | 3.6% | ||
|
Frazier Life Sciences Public Fund, L.P.
13D/A
Amendment 3
|
11.7% |
8/10/2026
Event 8/6/2026
|
|
| Frazier Life Sciences Public Fund, L.P. | 3.0% | ||
| FHMLSP, L.P. | 3.0% | ||
| FHMLSP, L.L.C. | 3.0% | ||
| Frazier Life Sciences X, L.P. | 10.8% | ||
| FHMLS X, L.P. | 10.8% | ||
| FHMLS X, L.L.C. | 10.8% | ||
| Frazier Life Sciences XI, L.P. | 0% | ||
| FHMLS XI, L.P. | 0% | ||
| FHMLS XI, L.L.C. | 0% | ||
| James N. Topper | 11.7% | ||
| Patrick J. Heron | 11.7% | ||
|
Orbimed Advisors LLC
13D/A
Amendment 3
|
6.4% |
8/10/2026
Event 8/6/2026
|
|
| Orbimed Advisors LLC | 6.4% | ||
| Orbimed Capital GP VII LLC | 5.2% | ||
| Orbimed Genesis GP LLC | 1.2% | ||
| BlackRock, Inc. 13G | 5.5% |
7/29/2026
Event 6/30/2026
|
|
|
Wellington Management Group LLP
13G/A
Amendment 5
|
10.5% |
7/8/2026
Event 6/30/2026
|
|
| Wellington Management Group LLP | 10.5% | ||
| Wellington Group Holdings LLP | 10.5% | ||
| Wellington Investment Advisors Holdings LLP | 10.5% | ||
| Wellington Management Company LLP | 9.8% | ||
|
FMR LLC
13G/A
Amendment 1
|
11.2% |
7/8/2026
Event 6/30/2026
|
|
| FMR LLC | 11.2% | ||
| Abigail P. Johnson | 11.2% | ||
|
Paradigm Biocapital Advisors LP
13G
|
5.2% |
6/24/2026
Event 6/16/2026
|
|
| Paradigm BioCapital Advisors LP | 5.2% | ||
| Paradigm BioCapital Advisors GP LLC | 5.2% | ||
| Senai Asefaw, M.D. | 5.2% | ||
| Paradigm BioCapital International Fund Ltd. | 4.6% | ||
|
FMR LLC
13G
|
6.2% |
5/6/2026
Event 3/31/2026
|
|
| FMR LLC | 6.2% | ||
| Abigail P. Johnson | 6.2% | ||
| BlackRock, Inc. 13G/A Amendment 1 | 4.8% |
4/27/2026
Event 3/31/2026
|
|
|
Orbimed Advisors LLC
13D/A
Amendment 2
|
7.7% |
2/11/2026
Event 2/5/2026
|
|
| Orbimed Advisors LLC | 7.7% | ||
| Orbimed Capital GP VII LLC | 6.3% | ||
| OrbiMed Genesis GP LLC | 1.4% | ||
|
Wellington Management Group LLP
13G/A
Amendment 4
|
7.5% |
2/10/2026
Event 12/31/2025
|
|
| Wellington Management Group LLP | 7.5% | ||
| Wellington Group Holdings LLP | 7.5% | ||
| Wellington Investment Advisors Holdings LLP | 7.5% | ||
| Wellington Management Company LLP | 7.3% | ||
| BlackRock, Inc. 13G | 5.1% |
1/21/2026
Event 12/31/2025
|
|
| P. Kent Hawryluk 13G/A Amendment 1 | 4.3% |
11/14/2025
Event 9/30/2025
|
|
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. 13G/A Amendment 1 | 4.5% |
11/12/2025
Event 9/30/2025
|
|
|
New Enterprise Associates 17, L.P.
13D/A
Amendment 1
|
8.1% |
11/10/2025
Event 11/6/2025
|
|
| New Enterprise Associates 17, L.P. | 8.1% | ||
| NEA Partners 17, L.P. | 8.1% | ||
| Nea 17 GP, LLC | 8.1% | ||
| Forest Baskett | 8.1% | ||
| Ali Behbahani | 8.1% | ||
| Carmen Chang | 8.1% | ||
| Anthony A. Florence, Jr. | 8.1% | ||
| Mohamad H. Makhzoumi | 8.1% | ||
| Edward T. Mathers | 8.1% | ||
| Scott D. Sandell | 8.1% | ||
| Paul Walker | 8.1% | ||
| Rick Yang | 8.1% | ||
|
Wellington Management Group LLP
13G/A
Amendment 3
|
10.8% |
10/6/2025
Event 9/30/2025
|
|
| Wellington Management Group LLP | 10.8% | ||
| Wellington Group Holdings LLP | 10.8% | ||
| Wellington Investment Advisors Holdings LLP | 10.8% | ||
| Wellington Management Company LLP | 10.6% | ||
|
Norwest Venture Partners XVI, LP
13D/A
Amendment 1
|
4.8% |
9/30/2025
Event 9/26/2025
|
|
| Norwest Venture Partners XVI, LP | 4.8% | ||
| Genesis VC Partners XVI, LLC | 4.8% | ||
| NVP Associates, LLC | 4.8% | ||
| Jeffrey Crowe | 4.8% | ||
| Jon Erik Kossow | 4.8% | ||
| Tiba Aynechi | 4.8% | ||
|
Frazier Life Sciences Public Fund, L.P.
13D/A
Amendment 2
|
11.7% |
9/30/2025
Event 9/26/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 2.5% | ||
| FHMLSP, L.P. | 2.5% | ||
| FHMLSP, L.L.C. | 2.5% | ||
| Frazier Life Sciences Public Overage Fund, L.P. | 0.7% | ||
| FHMLSP Overage, L.P. | 0.7% | ||
| FHMLSP Overage, L.L.C. | 0.7% | ||
| Frazier Life Sciences X, L.P. | 11.7% | ||
| FHMLS X, L.P. | 11.7% | ||
| FHMLS X, L.L.C. | 11.7% | ||
| Frazier Life Sciences XI, L.P. | 0% | ||
| FHMLS XI, L.P. | 0% | ||
| FHMLS XI, L.L.C. | 0% | ||
| James N. Topper | 11.7% | ||
| Patrick J. Heron | 11.7% | ||
|
Orbimed Advisors LLC
13D/A
Amendment 1
|
9.0% |
9/30/2025
Event 9/26/2025
|
|
| Orbimed Advisors LLC | 9.0% | ||
| Orbimed Capital GP VII LLC | 7.3% | ||
| OrbiMed Genesis GP LLC | 1.7% | ||
|
Frazier Life Sciences Public Fund, L.P.
13D/A
Amendment 1
|
13.6% |
8/20/2025
Event 8/18/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 3.3% | ||
| FHMLSP, L.P. | 3.3% | ||
| FHMLSP, L.L.C. | 3.3% | ||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.0% | ||
| FHMLSP Overage, L.P. | 1.0% | ||
| FHMLSP Overage, L.L.C. | 1.0% | ||
| Frazier Life Sciences X, L.P. | 13.6% | ||
| FHMLS X, L.P. | 13.6% | ||
| FHMLS X, L.L.C. | 13.6% | ||
| Frazier Life Sciences XI, L.P. | 0% | ||
| FHMLS XI, L.P. | 0% | ||
| FHMLS XI, L.L.C. | 0% | ||
| James N. Topper | 13.6% | ||
| Patrick J. Heron | 13.6% | ||
| Albert Cha | 0% | ||
| James Brush | 0% | ||
| Daniel Estes | 0% | ||
|
Deep Track Capital, LP
13G/A
Amendment 1
|
6.6% |
8/14/2025
Event 6/30/2025
|
|
| Deep Track Capital, LP | 6.6% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 6.6% | ||
| David Kroin | 6.6% | ||
|
Wellington Management Group LLP
13G/A
Amendment 2
|
6.8% |
8/12/2025
Event 6/30/2025
|
|
| Wellington Management Group LLP | 6.8% | ||
| Wellington Group Holdings LLP | 6.8% | ||
| Wellington Investment Advisors Holdings LLP | 6.8% | ||
| Wellington Management Company LLP | 6.8% | ||
|
Wellington Management Group LLP
13G/A
Amendment 1
|
7.9% |
5/12/2025
Event 3/31/2025
|
|
| Wellington Management Group LLP | 7.9% | ||
| Wellington Group Holdings LLP | 7.9% | ||
| Wellington Investment Advisors Holdings LLP | 7.9% | ||
| Wellington Management Company LLP | 7.8% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 4 | 635 | $37.2 k |
| 2026 Q2 | 181 | 56.8 M | $3.08 B |
| 2026 Q1 | 164 | 53.0 M | $1.58 B |
| 2025 Q4 | 146 | 48.4 M | $1.53 B |
| 2025 Q3 | 136 | 47.8 M | $836 M |
| 2025 Q2 | 95 | 36.9 M | $421 M |
| 2025 Q1 | 80 | 35.7 M | $263 M |
| 2024 Q4 | 64 | 32.9 M | $606 M |
| 2024 Q3 | 46 | 30.3 M | $784 M |